Skip to main content
  • Bookmarks
  • Register
  • Login

NIH OIR/OTT Logo

Main Menu

  • Partnerships

    Partnerships

    These links provide access to the information that is commonly needed for companies or organizations interested in partnering with NIH. The information here covers the process from researching available technologies through fees associated.

    • Overview
    • Opportunities
    • Featured Technologies
    • Collaboration / CRADAs
    • Licensing Process
    • Forms / Model Agreements
    • Startups
    • Non-Profits
    • License Materials
    • Licensing FAQs
    • Business Opportunities
    • Product Showcase
    • Product Pipeline
    • Federal Register Notices

    The NIH cannot commercialize its discoveries even with its considerable size and resources — it relies instead upon partners. Typically, a royalty-bearing exclusive license agreement with the right to sublicense is given to a company from NIH to use patents, materials, or other assets to bring a therapeutic or vaccine product concept to market.

  • Royalties

    Royalties

    Information for inventors and licensees on the administration of royalties.

    • Information for NIH Inventors
    • Information for Licensees
    • License Notices / Reports
    • Royalty Coordinators
    • NIH Payment Center
    • CDC Payment Center

    Each year, hundreds of new inventions are made at NIH and CDC laboratories. Nine NIH Institutes or Centers (ICs) transfer NIH and CDC inventions through licenses to the private sector for further research and development and eventual commercialization.

  • Reports

    Reports

    These links provide access to reports tracking the success of NIH licensed products.

    • Annual Reports
    • Tech Transfer Statistics
    • Tech Transfer Metrics
    • Commercial Outcomes
    • HHS License-Based Vaccines & Therapeutics
    • Public Health & Economic Impact Study
    • Stories of Discovery
    • Chen Lecture Videos
    • NIH Patents and Active Patent Commercialization Licenses
    • Media Room
    • Tech Transfer Newsletters
    • NIH Patents and Patent Applications

    The NIH, CDC and FDA Intramural Research Programs are exceptionally innovative as exemplified by the many products currently on the market that benefit the public every day. Reports are generated from the commonly tracked metrics related to these products.

  • Resources

    Resources

    These links provide resources to those interested in the technology transfer activities at NIH.

    • Forms and Model Agreements
    • License Notices / Reports
    • Video Library
    • Inventor Resources
    • Presentations & Articles
    • FAQs
    • RSS Feeds
    • Inventor Showcase

    Past videos, lectures, presentations, and articles related to technology transfer at NIH are kept and made available to the public. These topics range from general technology transfer information to processes specific to NIH.

  • Policy & Regulations

    Policies & Regulations

    These links provide access to the policies and regulations surrounding partnering or collaborating with NIH.

    • Freedom of Information Act (FOIA)
    • PHS Technology Transfer Policy
    • Policies & Reports
    • Useful Links

    If a company would like to acquire rights to use or commercialize either an unpatented material, or a patented or patent-pending invention, a license is required. There are numerous policies and regulations surrounding the transfer or a technology from the NIH to a company or organization.

  • About

    About Us

    These links provide information about the Office of Technology Transfer.

    • Contact Us
    • Staff Directory
    • Management
    • FAQs
    • HHS Tech Transfer Offices & Contacts
    • Careers in Tech Transfer
    • Location & Directions
    • Feedback

    The NIH Office of Technology Transfer (OTT) plays a strategic role by supporting the patenting and licensing efforts of our NIH ICs. OTT protects, monitors, markets and manages the wide range of NIH discoveries, inventions, and other intellectual property as mandated by the Federal Technology Transfer Act and related legislation.

Breadcrumb

  1. Home
  2. Taxonomy
  3. Term
  4. NIAID

Method Of In Vitro T-Cell Diffeerentiation Of CD34 Progenitor Cells

  • Read more about Method Of In Vitro T-Cell Diffeerentiation Of CD34 Progenitor Cells
US Application 60/162,574
Filed on 1999-10-29

Recovery of Recombinant Human Metapneumovirus (HPMV) From CDNA and Use of Recombinant HMPV in Immunogenic Compositions and As Vectors to Elicit Immune Responses Against HMPV and Other Human Pathogens

  • Read more about Recovery of Recombinant Human Metapneumovirus (HPMV) From CDNA and Use of Recombinant HMPV in Immunogenic Compositions and As Vectors to Elicit Immune Responses Against HMPV and Other Human Pathogens
US Application 60/451,119
Filed on 2003-02-28

Paramyxoviruses As Gene Transfer Vectors To Lung Cells

  • Read more about Paramyxoviruses As Gene Transfer Vectors To Lung Cells
US Application 60/326,535
Filed on 2001-09-28

P. Ariasi Polypeptides And P. Perniciosus Polypeptides Methods Of Use

  • Read more about P. Ariasi Polypeptides And P. Perniciosus Polypeptides Methods Of Use
US Application 60/425,852
Filed on 2002-11-12

Identification of Chimpanzee FAB Fragments by Repertoire Cloning and Production of a Full-Length Humanized IgG1 Antibody Highly Efficient Neutralization of Dengue Type 4 Virus

  • Read more about Identification of Chimpanzee FAB Fragments by Repertoire Cloning and Production of a Full-Length Humanized IgG1 Antibody Highly Efficient Neutralization of Dengue Type 4 Virus
US Application 60/528,161
Filed on 2003-12-08

Dengue Tetravalent Vaccine Containing a Common 30 Nucleotide Deletion in The 3'-UTR of Dengue Types 1,2,3, And 4

  • Read more about Dengue Tetravalent Vaccine Containing a Common 30 Nucleotide Deletion in The 3'-UTR of Dengue Types 1,2,3, And 4
US Application 60/436,500
Filed on 2002-12-23

Safer Attentuated Virus Vaccines with Missing or Diminished Latency of Infection

  • Read more about Safer Attentuated Virus Vaccines with Missing or Diminished Latency of Infection
US Application 60/423,603
Filed on 2002-11-05

HTLV-1-Cell Binding & Inhibition

  • Read more about HTLV-1-Cell Binding & Inhibition
US Application 60/422,803
Filed on 2002-10-30

Recovery of Recombinant Human Parainfluenza Virus Type 2 (HPIV2) From cDNA and Use of Recombinant HPIV2 in Immunogenic Compositions and as Vectors to Elicit Immune Responses Against PIV and Other Human Pathogens.

  • Read more about Recovery of Recombinant Human Parainfluenza Virus Type 2 (HPIV2) From cDNA and Use of Recombinant HPIV2 in Immunogenic Compositions and as Vectors to Elicit Immune Responses Against PIV and Other Human Pathogens.
US Application 60/412,053
Filed on 2002-09-18

Non-Viral Mammalian Expression Vector

  • Read more about Non-Viral Mammalian Expression Vector
US Application 60/413,117
Filed on 2002-09-24

Pagination

  • First page « First
  • Previous page ‹‹
  • …
  • Page 97
  • Page 98
  • Page 99
  • Page 100
  • Page 101
  • Page 102
  • Page 103
  • Page 104
  • Page 105
  • …
  • Next page ››
  • Last page Last »
Subscribe to NIAID
NIH White Technology Transfer Logo

Return to Top

  • About
  • Privacy Notice
  • Accessibility
  • Web Policies & Notices
  • Open Data
  •  
  • For NIH Staff Only
  • HHS
  • NIH
  • HHS Vulnerability Disclosure
  • Connect
  • Twitter
  • LinkedIn
  • Contact
  • Feedback

Office of Technology Transfer, Office of Intramural Research, National Institutes of Health